Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01740336




Registration number
NCT01740336
Ethics application status
Date submitted
30/11/2012
Date registered
4/12/2012
Date last updated
24/04/2017

Titles & IDs
Public title
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
Scientific title
A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Secondary ID [1] 0 0
2012-003262-41
Secondary ID [2] 0 0
GO28509
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GDC-0941
Treatment: Drugs - Placebo
Treatment: Drugs - Paclitaxel

Experimental: A: Paclitaxel, GDC-0941 - Participants will receive GDC-091 260 milligrams (mg) orally in repeated rounds of once daily (QD) dosing for 5 consecutive days followed by 2 consecutive days during which GDC-0941 will not be administered (5/7-day schedule). This 5/7-day schedule will be repeated weekly in each 28-day cycle until disease progression or intolerable toxicity. Participants will receive 90 milligrams per square meter (mg/m\^2) intravenously (IV) weekly for 3 out of 4 weeks in every 28-day cycle.

Placebo comparator: B: Paclitaxel, Placebo - Participants will receive placebo matching to GDC-0941 on the 5/7-day schedule along with 90 mg/m\^2 IV weekly for 3 out of 4 weeks in every 28-day cycle.


Treatment: Drugs: GDC-0941
GDC-0941 will be administered QD orally for 5 consecutive days each week.

Treatment: Drugs: Placebo
Placebo matching to GDC-0941

Treatment: Drugs: Paclitaxel
Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS) Assessed as per Modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)
Timepoint [1] 0 0
From the time of randomization until disease progression or death from any cause (up to approximately 3 years)
Secondary outcome [1] 0 0
Percentage of Participants With Adverse Events
Timepoint [1] 0 0
From randomization up to approximately 3 years
Secondary outcome [2] 0 0
Percentage of Participants With Objective Tumor Response Assessed as per Modified RECIST v1.1
Timepoint [2] 0 0
From first observation of an objective tumor response until disease progression (up to approximately 3 years)
Secondary outcome [3] 0 0
Percentage of Participants Acheiving Clinical Benefit (Partial Response, Complete Response or Stable Disease Lasting for at Least 6 Months) Assessed as per Modified RECIST v1.1
Timepoint [3] 0 0
From randomization until disease progression (up to approximately 3 years)
Secondary outcome [4] 0 0
Duration of Confirmed Objective Response Assessed as per Modified RECIST v1.1
Timepoint [4] 0 0
From first observation of an objective tumor response until disease progression (up to approximately 3 years)
Secondary outcome [5] 0 0
Population Pharmacokinetics (PK) for GDC-0941
Timepoint [5] 0 0
Day 8 of Cycle 1 and Day 1 of Cycle 6 (cycle length=28 days)
Secondary outcome [6] 0 0
Population PK for Paclitaxel
Timepoint [6] 0 0
Day 1 of Cycle 1 (cycle length=28 days)

Eligibility
Key inclusion criteria
* Histologically or cytologically confirmed adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease
* Human epidermal growth factor receptor 2 (HER2)-negative and hormone receptor (HR) (estrogen receptor and/or progesterone receptor)-positive disease as defined by local guidelines
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Adequate hematologic and end organ function
* Women of childbearing potential must agree to remain abstinent or to use two adequate methods of contraception, including at least one method with a failure rate of less than (<) 1 percent (%) per year, during the treatment period and for at least 30 days after the last dose of study treatment or 6 months after discontinuation of paclitaxel, whichever is longer
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior non-capecitabine chemotherapy for locally recurrent or metastatic disease
* Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor for advanced or metastatic breast cancer
* History of intolerance to a taxane-containing therapy
* History of clinically significant cardiac or pulmonary dysfunction
* History of malabsorption syndrome or other condition that would interfere with enteral absorption
* Clinically significant history of liver disease
* Active autoimmune disease or active inflammatory disease
* Immunocompromised status due to current known active infection with human immunodeficiency virus (HIV) or due to the use of immunosuppressive therapies for other conditions
* Need for current chronic corticosteroid therapy
* Pregnant, lactating, or breastfeeding women
* Current severe, uncontrolled systemic disease
* Known untreated or active central nervous system (CNS) metastases

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/02/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/12/2015
Sample size
Target
Accrual to date
Final
183
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [3] 0 0
Port Macquarie Base Hospital;North Coast Cancer Institute - Port Macquarie
Recruitment hospital [4] 0 0
Sydney Haematology & Oncology Clinic - Wahroonga
Recruitment hospital [5] 0 0
Calvary Mater Newcastle; Medical Oncology - Waratah
Recruitment hospital [6] 0 0
Border Medical Oncology - Wodonga
Recruitment hospital [7] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [8] 0 0
Mater Adult Hospital - Mackay
Recruitment hospital [9] 0 0
Ashford Cancer Center Research - Kurralta Park
Recruitment hospital [10] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [11] 0 0
Bendigo Hospital; Oncology - Bendigo
Recruitment hospital [12] 0 0
Peninsula and South Eastern Haematology and Oncology Grou - Frankston
Recruitment hospital [13] 0 0
Royal Perth Hospital; Medical Oncology - Perth
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
2444 - Port Macquarie
Recruitment postcode(s) [4] 0 0
2076 - Wahroonga
Recruitment postcode(s) [5] 0 0
2298 - Waratah
Recruitment postcode(s) [6] 0 0
3690 - Wodonga
Recruitment postcode(s) [7] 0 0
4029 - Herston
Recruitment postcode(s) [8] 0 0
4740 - Mackay
Recruitment postcode(s) [9] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [10] 0 0
7000 - Hobart
Recruitment postcode(s) [11] 0 0
3550 - Bendigo
Recruitment postcode(s) [12] 0 0
3199 - Frankston
Recruitment postcode(s) [13] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maine
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
South Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Utah
Country [20] 0 0
United States of America
State/province [20] 0 0
Virginia
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
Austria
State/province [22] 0 0
Graz
Country [23] 0 0
Austria
State/province [23] 0 0
Salzburg
Country [24] 0 0
Austria
State/province [24] 0 0
Wels
Country [25] 0 0
Austria
State/province [25] 0 0
Wien
Country [26] 0 0
Belgium
State/province [26] 0 0
Brussels
Country [27] 0 0
Belgium
State/province [27] 0 0
Edegem
Country [28] 0 0
Belgium
State/province [28] 0 0
Leuven
Country [29] 0 0
Belgium
State/province [29] 0 0
Mons
Country [30] 0 0
Belgium
State/province [30] 0 0
Namur
Country [31] 0 0
Belgium
State/province [31] 0 0
Wilrijk
Country [32] 0 0
Czechia
State/province [32] 0 0
Brno
Country [33] 0 0
Czechia
State/province [33] 0 0
Liberec
Country [34] 0 0
Czechia
State/province [34] 0 0
Pardubice
Country [35] 0 0
Czechia
State/province [35] 0 0
Prague
Country [36] 0 0
Czechia
State/province [36] 0 0
Praha 2
Country [37] 0 0
Czechia
State/province [37] 0 0
Praha 4 - Krc
Country [38] 0 0
Korea, Republic of
State/province [38] 0 0
Cheongju-si
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Seoul
Country [40] 0 0
Spain
State/province [40] 0 0
Barcelona
Country [41] 0 0
Spain
State/province [41] 0 0
Jaen
Country [42] 0 0
Spain
State/province [42] 0 0
Madrid
Country [43] 0 0
United Kingdom
State/province [43] 0 0
Brighton
Country [44] 0 0
United Kingdom
State/province [44] 0 0
Guildford
Country [45] 0 0
United Kingdom
State/province [45] 0 0
Leicester
Country [46] 0 0
United Kingdom
State/province [46] 0 0
London
Country [47] 0 0
United Kingdom
State/province [47] 0 0
Manchester
Country [48] 0 0
United Kingdom
State/province [48] 0 0
Newcastle upon Tyne
Country [49] 0 0
United Kingdom
State/province [49] 0 0
Nottingham
Country [50] 0 0
United Kingdom
State/province [50] 0 0
Stoke on Trent
Country [51] 0 0
United Kingdom
State/province [51] 0 0
Truro
Country [52] 0 0
United Kingdom
State/province [52] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Genentech, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Genentech, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01740336